Clinical trial
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
NCT03966651 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
- Lead sponsor
- Institut Claudius Regaud
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 17, 2023
- Completion date
- August 30, 2024
- Enrollment
- 1 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.